187 related articles for article (PubMed ID: 17179223)
1. Members of the glutathione and ABC-transporter families are associated with clinical outcome in patients with diffuse large B-cell lymphoma.
Andreadis C; Gimotty PA; Wahl P; Hammond R; Houldsworth J; Schuster SJ; Rebbeck TR
Blood; 2007 Apr; 109(8):3409-16. PubMed ID: 17179223
[TBL] [Abstract][Full Text] [Related]
2. A redox signature score identifies diffuse large B-cell lymphoma patients with a poor prognosis.
Tome ME; Johnson DB; Rimsza LM; Roberts RA; Grogan TM; Miller TP; Oberley LW; Briehl MM
Blood; 2005 Nov; 106(10):3594-601. PubMed ID: 16081686
[TBL] [Abstract][Full Text] [Related]
3. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.
Sakhinia E; Glennie C; Hoyland JA; Menasce LP; Brady G; Miller C; Radford JA; Byers RJ
Blood; 2007 May; 109(9):3922-8. PubMed ID: 17255358
[TBL] [Abstract][Full Text] [Related]
4. Membrane PKC-beta 2 protein expression predicts for poor response to chemotherapy and survival in patients with diffuse large B-cell lymphoma.
Espinosa I; Briones J; Bordes R; Brunet S; Martino R; Sureda A; Prat J; Sierra J
Ann Hematol; 2006 Sep; 85(9):597-603. PubMed ID: 16830142
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma.
Barr PM; Miller TP; Friedberg JW; Peterson DR; Baran AM; Herr M; Spier CM; Cui H; Roe DJ; Persky DO; Casulo C; Littleton J; Schwartz M; Puvvada S; Landowski TH; Rimsza LM; Dorr RT; Fisher RI; Bernstein SH; Briehl MM
Blood; 2014 Aug; 124(8):1259-65. PubMed ID: 25016003
[TBL] [Abstract][Full Text] [Related]
6. Characterization of three B-cell lymphoma cell lines from chemotherapy resistant patients with respect to in vitro sensitivity to 21 antitumor agents, ABC-transporter expression and cellular redox status.
Bracht K; Kiefer T; Dölken G; Bednarski PJ
J Cancer Res Clin Oncol; 2007 Dec; 133(12):957-67. PubMed ID: 17562080
[TBL] [Abstract][Full Text] [Related]
7. CHOP-R therapy overcomes the adverse prognostic influence of BCL-2 expression in diffuse large B-cell lymphoma.
Wilson KS; Sehn LH; Berry B; Chhanabhai M; Fitzgerald CA; Gill KK; Klasa R; Skinnider B; Sutherland J; Connors JM; Gascoyne RD
Leuk Lymphoma; 2007 Jun; 48(6):1102-9. PubMed ID: 17577773
[TBL] [Abstract][Full Text] [Related]
8. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
9. Loss of O6-methylguanine-DNA methyltransferase protein expression is a favorable prognostic marker in diffuse large B-cell lymphoma.
Ohno T; Hiraga J; Ohashi H; Sugisaki C; Li E; Asano H; Ito T; Nagai H; Yamashita Y; Mori N; Kinoshita T; Naoe T
Int J Hematol; 2006 May; 83(4):341-7. PubMed ID: 16757436
[TBL] [Abstract][Full Text] [Related]
10. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
[TBL] [Abstract][Full Text] [Related]
11. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma.
Rosenwald A; Wright G; Chan WC; Connors JM; Campo E; Fisher RI; Gascoyne RD; Muller-Hermelink HK; Smeland EB; Giltnane JM; Hurt EM; Zhao H; Averett L; Yang L; Wilson WH; Jaffe ES; Simon R; Klausner RD; Powell J; Duffey PL; Longo DL; Greiner TC; Weisenburger DD; Sanger WG; Dave BJ; Lynch JC; Vose J; Armitage JO; Montserrat E; López-Guillermo A; Grogan TM; Miller TP; LeBlanc M; Ott G; Kvaloy S; Delabie J; Holte H; Krajci P; Stokke T; Staudt LM;
N Engl J Med; 2002 Jun; 346(25):1937-47. PubMed ID: 12075054
[TBL] [Abstract][Full Text] [Related]
12. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
13. Dysregulated MDR1 by PRDM1/Blimp1 Is Involved in the Doxorubicin Resistance of Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.
Qing K; Jin Z; Xu Z; Wang W; Li X; Zhang Y; Wang L; Zhu H; Xiang R; Wu S; Li R; Jiang G; Xue K; Li J
Chemotherapy; 2022; 67(1):12-23. PubMed ID: 34844236
[TBL] [Abstract][Full Text] [Related]
14. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
15. Multidrug resistance: molecular mechanisms and clinical relevance.
Ling V
Cancer Chemother Pharmacol; 1997; 40 Suppl():S3-8. PubMed ID: 9272126
[TBL] [Abstract][Full Text] [Related]
16. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value for long-term survival in diffuse large B-cell lymphoma.
Gao Q; Li Z; Meng L; Ma J; Xi Y; Wang T
Aging (Albany NY); 2020 Nov; 12(22):23275-23295. PubMed ID: 33221755
[TBL] [Abstract][Full Text] [Related]
17. BCRP gene polymorphisms are associated with susceptibility and survival of diffuse large B-cell lymphoma.
Hu LL; Wang XX; Chen X; Chang J; Li C; Zhang Y; Yang J; Jiang W; Zhuang SM
Carcinogenesis; 2007 Aug; 28(8):1740-4. PubMed ID: 17494054
[TBL] [Abstract][Full Text] [Related]
18. Molecular diagnosis of lymphoma: outcome prediction by gene expression profiling in diffuse large B-cell lymphoma.
Last K; Debarnardi S; Lister TA
Methods Mol Med; 2005; 115():15-63. PubMed ID: 15998962
[TBL] [Abstract][Full Text] [Related]
19. BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis.
Punnoose E; Peale FV; Szafer-Glusman E; Lei G; Bourgon R; Do AD; Kim E; Zhang L; Farinha P; Gascoyne RD; Munoz FJ; Martelli M; Mottok A; Salles GA; Sehn LH; Seymour JF; Trnĕný M; Oestergaard MZ; Mundt KE; Vitolo U
Clin Lymphoma Myeloma Leuk; 2021 Apr; 21(4):267-278.e10. PubMed ID: 33303421
[TBL] [Abstract][Full Text] [Related]
20. Promoter hypermethylation of the DNA-repair gene O6-methylguanine-DNA methyltransferase and p53 mutation in diffuse large B-cell lymphoma.
Hiraga J; Kinoshita T; Ohno T; Mori N; Ohashi H; Fukami S; Noda A; Ichikawa A; Naoe T
Int J Hematol; 2006 Oct; 84(3):248-55. PubMed ID: 17050200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
